BioPharmSignal logoBioPharmSignal

Biotech News

Annexon to Participate in Upcoming June Investor Conferences

Annexon, Inc. (ANNX)Annexon, Inc.Company update

BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love,

Related news

ANNXAnnexon, Inc.2026-08-06 12:00 EST

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

ANNXAnnexon, Inc.2026-07-30 20:01 EST

Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance

TNXPTonix Pharmaceuticals2026-08-05 11:00 EST

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

ECORelectroCore2026-08-03 12:00 EST

electroCore to Participate in Upcoming Investor Conferences

HRMYHarmony Biosciences2026-05-27 12:05 EST

Harmony Biosciences to Participate in Upcoming Investor Conferences

AXSMAxsome2026-05-27 11:00 EST

Axsome Therapeutics to Participate in Upcoming Investor Conferences

NBIXNeurocrine Biosciences2026-05-26 20:01 EST

Neurocrine Biosciences to Present at Upcoming Investor Conferences in June

TNXPTonix Pharmaceuticals2026-05-12 20:30 EST

Tonix Pharmaceuticals to Participate in Two Investor Conferences in May

CGTXCognition Therapeutics2026-06-01 11:30 EST

Cognition Therapeutics Participating in Upcoming Investor Conferences

HRMYHarmony Biosciences2026-08-06 12:05 EST

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

View all latest news

Annexon, Inc.

Classical Complement Inhibition Annexon develops therapies that inhibit the classical complement pathway, which can drive harmful inflammation and tissue damage in neurologic, ophthalmic and autoimmune diseases. Vonaprument Vonaprument is a complement inhibitor in pivotal development for geographic atrophy, an advanced form of dry...

Recent company news

ANNXAnnexon, Inc.2026-08-06 12:00 EST

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

ANNXAnnexon, Inc.2026-07-30 20:01 EST

Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance

ANNXAnnexon, Inc.2026-07-16 20:05 EST

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

ANNXAnnexon, Inc.2026-07-14 20:05 EST

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026

ANNXAnnexon, Inc.2026-06-16 20:05 EST

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
5.60 USD
Market cap
861.81M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States